Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monopar Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer focused on ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers. Its 8-K reports furnish financial results, business updates, Regulation FD clinical presentations, conference materials and executive leadership changes, including ALXN1840 Phase 2 and Phase 3 analyses and MNPR-101 program regulatory updates.
Proxy and material-event filings cover shareholder voting matters, board governance, executive compensation, pay-versus-performance tables, capital-structure disclosures and material agreements. The filing record also provides formal context for reported operating results, financing activity and disclosures tied to investigational drug development and Nasdaq-listed common stock.
MNPR received a Form 144/A filing indicating that Arthur Klausner may sell up to 5,000 shares of common stock through MLPFS at One Bryant Park, New York, with sales permissible on or after 07/08/2026 on NASDAQ. The shares relate to multiple restricted stock unit vestings granted as part of the issuer’s equity compensation plan between 09/30/2020 and 12/31/2023, each described as equity awards to Klausner.
Monopar Therapeutics’ Chief Financial Officer Vu Quan Anh reported routine equity compensation activity tied to restricted stock units. On the vesting date, 1,228 restricted stock units converted into the same number of common shares. The company withheld 507 shares to cover tax obligations, a non‑market disposition.
Following these transactions, Vu Quan Anh directly holds 2,221 shares of common stock. He also retains 8,598 unvested restricted stock units from a 9,826-unit grant awarded on December 2, 2025, which began vesting on June 30, 2026 and is scheduled to fully vest by December 31, 2029.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported compensation-related stock activity. On June 30, 2026, 12,873 restricted stock units vested and settled into the same number of common shares. The issuer withheld 4,084 shares at $92.59 per share to cover applicable tax obligations.
Following these transactions, Robinson holds 99,267 shares of Monopar common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. The filing reflects routine RSU vesting and associated tax-withholding dispositions, not open-market purchases or sales.
Monopar Therapeutics Chief Operating Officer Andrew Cittadine reported routine equity compensation activity involving restricted stock units and related tax withholding. On June 30, 2026, 5,254 restricted stock units converted into the same number of common shares at a stated price of $0.00 per share. Of the resulting shares, 2,309 were withheld by the company to cover applicable withholding taxes tied to the vesting event. Following these transactions, Cittadine directly held 57,923 shares of Monopar common stock and 39,499 restricted stock units that remain outstanding and subject to future vesting schedules.
Monopar Therapeutics director Nicole Sweeny received a grant of stock options, acquiring rights to 1,284 shares of common stock. The options have an exercise price of $87.68 per share and expire on June 26, 2036.
The grant vests in two equal installments, with 50% vesting on September 30, 2026 and the remaining 50% vesting on December 31, 2026. Following this grant, Sweeny holds options on 1,284 shares directly. This is a compensation-related award rather than an open-market stock purchase or sale.
Monopar Therapeutics director Nicole Sweeny filed an initial ownership report on Form 3. This filing establishes her status as an insider of the company but does not show any stock transactions, option exercises, or specific shareholdings in the provided data.
Monopar Therapeutics reported that the U.S. Food and Drug Administration granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline), its late-stage candidate for treating Wilson disease. This designation may allow Monopar, if ALXN1840 is approved, to receive a pediatric Priority Review Voucher, which can shorten FDA review time or be sold to another company.
ALXN1840 is an oral, once-daily, first-in-class albumin tripartite complex activator designed to tightly bind excess copper and improve copper balance. In a Phase 3 pivotal trial over 48 weeks, it met the primary endpoint with copper mobilization greater than standard of care, with durable clinical improvement and a favorable safety profile across 645 patient-years in 266 patients.
Monopar Therapeutics is presenting new analyses from its Phase 3 FoCus trial of ALXN1840 in Wilson disease, showing greater neurologic and overall clinical benefit versus standard of care in patients with neurologic symptoms at baseline.
Across Phase 2 and Phase 3 studies, ALXN1840 was given to 266 patients over 645 patient-years, with a median treatment duration of 2.58 years and maximum exposure of more than 8 years. Drug-related serious adverse events occurred in 4.9% of patients, neurologic serious events in less than 1%, and no treatment-related deaths were reported. Monopar states that these results further support its planned New Drug Application submission to the FDA for ALXN1840 in mid-2026.
Monopar Therapeutics Inc. held its Annual Meeting on June 22, 2026, with 6,698,778 common shares entitled to vote and 5,760,392 shares represented in person or by proxy. Stockholders voted on directors, executive compensation, the 2026 Stock Incentive Plan, and the 2026 auditor.
All six director nominees were elected, with support ranging from 4,203,485 to 4,911,758 votes for each candidate, plus broker non-votes. Stockholders approved the advisory vote on named executive officer pay and the Company’s 2026 Stock Incentive Plan, and ratified BPM LLP as independent registered public accounting firm for the year ending December 31, 2026.